Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Lipocine Inc.

NASDAQ: LPCN · Life Sciences · 10 alerts · CIK 1535955

Share price
$1.66Close, Nov 16
Market cap
$18.4M
Shares outstanding
11.07MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Lipocine Inc. filings on SEC EDGAR ↗

6:11 AM ET 8-K
Regulatory Approval

Lipocine Regulatory Approval

Lipocine announced that Health Canada has approved TLANDO (testosterone undecanoate) capsules for testosterone replacement therapy in adult males. The product is licensed to Verity Pharmaceuticals, which plans to launch and commercialize the oral therapeutic in the Canadian market by the end of 2026.

Counterparty
Health Canada
6:16 AM ET 8-K
Clinical Trial Data

Lipocine Clinical Trial Data

Lipocine Inc. announced the initiation of BLOOM, a Phase 3 clinical study evaluating LPCN 1154 (oral brexanolone) for the treatment of postpartum depression. The study aims to enroll approximately 120 participants with first dosing expected in early Q4 2026, following exploratory findings from a prior trial that suggested rapid symptom relief.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.